Investigational drug · Phase 2
GFH009
Also called: SLS009
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Large B-cell Lymphoma, Hematologic Malignancies.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "GFH009"
First trial start
2021
May 10, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GFH009", any sponsor or status.
Conditions studied
As listed on its trial records.
- Large B-cell Lymphoma
- Hematologic Malignancies
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "GFH009" as an intervention, largest first.
- Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AMLPivotal-lookingRecruiting
Sellas Life Sciences GroupIndustry
NCT04588922 · 160 participants (planned) · Start May 10, 2021 · Primary completion Dec 30, 2026
Drug: SLS009; venetoclax and 1 more · For: Hematologic Malignancies
Sites: Birmingham, Alabama; Goodyear, Arizona; Phoenix, Arizona · 32 sites in all
- A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)Status unknown
Genfleet Therapeutics (Shanghai) Inc.Industry
NCT05934513 · 95 participants (planned) · Start Sep 6, 2023 · Primary completion Dec 30, 2025
Drug: GFH009 · For: Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Sites: Guanzhou, China
- A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCLRecruiting
Genfleet Therapeutics (Shanghai) Inc.Industry
NCT06375733 · 51 participants (planned) · Start Mar 20, 2024 · Primary completion Dec 31, 2026
Drug: GFH009; Zanubrutinib and 2 more · For: Large B-cell Lymphoma
Sites: Nanning, China; Zhengzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Advancements of Emerging Thiazole-Based CDKs Inhibitors for Cancer Therapy: From Hits to Clinical Candidates.
Luo M, Jiang S, Ma Y, et al. · Drug Dev Res 2026
- Preclinical metabolism and disposition of [14C]GFH009, a novel selective CDK9 inhibitor.
Wang L, Zhao JZ, Zhou FS, et al. · Xenobiotica 2024
- Development and validation of a sensitive UPLC-MS/MS analytical method for GFH009 in rat plasma and its application to toxicokinetics studies.
Liu Q, Zhao JZ, Zhou FS, et al. · Biomed Chromatogr 2024
- The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies.
Zhou F, Tang L, Le S, et al. · Oncotarget 2023
Also in development for Large B-cell Lymphoma
- SurovatamigAZD0486, TNB-486Phase 39 trials
AstraZeneca · B-cell Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Untreated Follicular Lymphoma
- CC-99282BMS-986369, GolcadomidePhase 37 trials
Bristol Myers Squibb · Lymphoma, Follicular, Large B-cell Lymphoma, Non-Hodgkin Lymphoma
- Rondecabtagene autoleucelLYL314Phase 32 trials
Lyell Immunopharma, Inc. · Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Relma-celCAR, CD19-targeted Chimeric Antigen Receptor T CellsPhase 23 trials
Shanghai Ming Ju Biotechnology Co., Ltd. · Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Multiple Myeloma
- Zugocabtagene geleucelCTX112Phase 23 trials
CRISPR Therapeutics AG · B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy
- EB103Phase 21 trial
Estrella Immunopharma, Inc. · B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.